The human oxidized low-density lipoprotein (OxLDL) ELISA kit is suitable for the quantitative analysis of OxLDL in various human sample types including serum, plasma, urine, saliva, tissue homogenates, and cell lysates. It offers a detection range of 1.56 mU/mL to 100 mU/mL and a sensitivity of 0.78 mU/mL. The assay principle is competitive, and the detection wavelength is at 450 nm. The assay time ranges from 1 to 5 hours, requiring a sample volume of 50-100 µl. This ELISA kit has been utilized in over 14 research papers, highlighting its reliability and widespread acceptance in the scientific community.
OxLDL is a critical biomarker associated with atherosclerosis and cardiovascular events, with studies showing its involvement in inflammatory responses and the development of atherosclerotic lesions [1][2][3][4][5]. The interaction of OxLDL with specific receptors and the formation of autoantibodies further emphasize its role in disease progression [6][7][8][5]. The correlation between OxLDL and other factors like the von Willebrand factor in chronic renal failure underscores its significance in various pathological conditions [9].
References:
[1] C. Meisinger, J. Baumert, N. Khuseyinova, H. Loewel, & W. Köenig, "Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population", Circulation, vol. 112, no. 5, p. 651-657, 2005. https://doi.org/10.1161/circulationaha.104.529297
[2] R. Kato, C. Mori, K. Kitazato, S. Arata, T. Obama, M. Moriet al., "Transient increase in plasma oxidized ldl during the progression of atherosclerosis in apolipoprotein e knockout mice", Arteriosclerosis Thrombosis and Vascular Biology, vol. 29, no. 1, p. 33-39, 2009. https://doi.org/10.1161/atvbaha.108.164723
[3] J. Frostegård, R. Wu, C. Lemne, T. Thulin, J. Witztum, & U. Fairé, "Circulating oxidized low-density lipoprotein is increased in hypertension", Clinical Science, vol. 105, no. 5, p. 615-620, 2003. https://doi.org/10.1042/cs20030152
[4] E. Lourida, A. Georgiadis, E. Papavasiliou, Α. Παπαθανασίου, A. Drosos, & A. Tselepis, "Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase a2", Arthritis Research & Therapy, vol. 9, no. 1, p. R19, 2007. https://doi.org/10.1186/ar2129
[5] D. Lopez, I. García-Valladares, C. Palafox‐Sánchez, I. Torre, a. Lopez, & L. Lopez, "Oxidized low-density lipoprotein/b 2 -glycoprotein i complexes and autoantibodies to oxlig-1/b 2 -glycoprotein i in patients with systemic lupus erythematosus and antiphospholipid syndrome", American Journal of Clinical Pathology, vol. 121, no. 3, p. 426-436, 2004. https://doi.org/10.1309/2aue-6hd4-w6tl-euu5
[6] R. Wu, U. Fairé, C. Lemne, J. Witztum, & J. Frostegård, "Autoantibodies to oxldl are decreased in individuals with borderline hypertension", Hypertension, vol. 33, no. 1, p. 53-59, 1999. https://doi.org/10.1161/01.hyp.33.1.53
[7] L. Lopez, D. Simpson, B. Hurley, & E. Matsuura, "Oxldl/β2gpi complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: pathogenic implications for vascular involvement", Annals of the New York Academy of Sciences, vol. 1051, no. 1, p. 313-322, 2005. https://doi.org/10.1196/annals.1361.073
[8] E. Matsuura, K. Kobayashi, B. Hurley, & L. Lopez, "Atherogenic oxidized low-density lipoprotein/β2-glycoprotein i (oxldl/β2gpi) complexes in patients with systemic lupus erythematosus and antiphospholipid syndrome", Lupus, vol. 15, no. 7, p. 478-483, 2006. https://doi.org/10.1191/0961203306lu2337oa
[9] P. Holvoet, J. Donck, M. Landeloos, E. Brouwers, K. Luijtens, J. Arnoutet al., "Correlation between oxidized low density lipoproteins and von willebrand factor in chronic renal failure", Thrombosis and Haemostasis, vol. 76, no. 05, p. 663-669, 1996. https://doi.org/10.1055/s-0038-1650639
